Dihydromyricetin, a plant-compound supplement used around drinking and for liver and blood-sugar support, has modest evidence: small trials in fatty liver or type 2 diabetes suggest lower blood sugar and better liver tests. Longer-life evidence comes only from cells and animals. Trials report no attributable side effects, but safety data stop at one year. It may interact with some medicines, including diabetes drugs. Long-term effects in healthy people are unknown. (Full Review)

Protocol

Metabolic and liver protocol

Two 150 mg capsules twice daily

For 3 months; 600 mg/day in a multi-ingredient tablet for 12 months

Sleep and stress protocol

200 mg once daily

For 20 days, taken at the same time each day

Whole vine tea alternative

10 g of vine tea daily

Supplying about 970 mg dihydromyricetin, for 1 month

Time to effect

Fasting glucose

Within 1 month

Vine tea trial in type 2 diabetes

Liver enzymes

3 months

Changes became clearer between 6 and 12 months

Sleep and stress

20 days

Self-reported, within the treated group

Benefits

Medium: Lower fasting glucose and insulin resistance; lower liver enzymes in fatty liver disease; sleep duration and perceived stress

Low: Lower LDL cholesterol; kidney function markers in type 2 diabetes; hangover symptoms; epigenetic skin age and wrinkles

Speculative: Reduced senescent-cell burden; longer lifespan in model organisms; protection against alcohol liver injury; reduced alcohol intake and withdrawal; brain aging and neurodegeneration; preserved muscle mass

Contraindications

Pregnancy and breastfeeding

Advanced liver disease (Child-Pugh Class B or C)

Children and adolescents under 18

Alcohol use disorder

Users of narrow-margin CYP3A4 drugs (tacrolimus, cyclosporine)

Key Interactions

Alcohol (tested with Japanese raisin tree extract): impairment not reliably reduced

Theoretical (inferred from mechanism)

Narrow-margin CYP3A4 drugs (tacrolimus, simvastatin): raised drug levels

CYP2D6 drugs (metoprolol, codeine)

Acetaminophen (over-the-counter)

Glucose-lowering drugs (insulin, glipizide): low blood glucose

Benzodiazepines and Z-drugs (diazepam, zolpidem): altered sedation

P-glycoprotein substrates (digoxin, dabigatran): digoxin toxicity or bleeding with dabigatran

Glucose-lowering supplements (berberine, cinnamon extract): low blood glucose

Sedating supplements (kava, valerian): drowsiness

Iron supplements and iron-rich meals: lower iron absorption

Risk & Side Effects

Low: Additive glucose lowering with diabetes medication; heavier drinking enabled by hangover relief

Speculative: Altered levels of co-administered drugs; altered response to sedatives; reduced iron absorption; unknown long-term safety

Monitoring

Marker	Target	Why
Fasting glucose	70–99 mg/dL	Expected to change: trials report reductions
HbA1c	4.0–5.6%	Tracks 3-month glucose
Fasting insulin	Not specified in the ER	Paired with fasting glucose for HOMA-IR
HOMA-IR	No established target; track change from own baseline	Insulin resistance; fell in one trial
ALT	29–33 U/L or less (men), 19–25 U/L or less (women)	Safety check and expected to change
GGT	Below the laboratory upper limit, often about 40–60 U/L	Fell in fatty liver trials
LDL cholesterol	Below 100 mg/dL	Fell in one trial

Cadence: Baseline panel before starting, repeated at 3 months, then every 6–12 months while use continues; home glucose checks during the first 2–4 weeks on glucose-lowering drugs

Qualitative Assessment

Self-rated sleep duration and morning mood
Perceived stress level
Next-day well-being after drinking, where used around alcohol
Digestive comfort and any new drowsiness when combined with other medications

Dihydromyricetin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment